Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Investor Day (March 2023)
31 slides from Senseonics's investor day presentation, March 2023
Slide 1: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Any statements in this presentation about future expectations, plans and prospects for Senseonics and its business, including statements regarding managements plans, objectives and goals for future operations (including preliminary targets for fut
Slide 2: PHC Disclaimer
PHC Disclaimer Information in this presentation relating to PHC Holdings Corporation (referred to in this disclaimer as “PHCHD”, “we” or “our”), including information relating to Ascensia Diabetes Care, was prepared by PHCHD solely for informational purposes. This document does not constitute an off
Slide 3: Today’s Agenda
Today’s Agenda Event and Eversense Introduction Tim Goodnow, CEO & President of Senseonics Priorities for Success Koichiro Sato, COO of PHC Eversense Market Opportunity & Commercial Strategy Robert Schumm, President of Ascensia Diabetes Care Eversense Product Pipeline Tim Goodnow, CEO & President of
Slide 4: Our Mission
The PHC Group Our Mission We contribute to the health of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people 4
Slide 5: PHC Group Overview
PHC Group Overview PHC Group is a global healthcare company with heritage in Japan. It provides solutions committed to solve the many challenges in healthcare as well as products and services of leading brands to customers involved in healthcare from research to diagnostics, treatments and preventio
Slide 6: PHC Group Approach to Value-Based Healthcare
PHC Group Approach to Value-Based Healthcare PHC Group will advance Value-Based Healthcare through targeted Growth Areas 6
Slide 7: Expanding CGM Will Be Our Growth Driver
Expanding CGM Will Be Our Growth Driver PHC Group businesses that will drive growth: Targeting to increase revenue in Growth Areas, especially expanding CGM is our key initiatives. (JPY) Overall Growth CAGR: 5.4% 420bn Personalized Testing 54 & Diagnostic Personalized Testing & Diagnostic 340.5bn 5
Slide 8: Ascensia Diabetes Care: Making Eversense® a Commercial Success
Ascensia Diabetes Care: Making Eversense® a Commercial Success
Slide 9: Introduction to Ascensia Diabetes Care
Introduction to Ascensia Diabetes Care Robert Schumm President and CEO, Ascensia Diabetes Care Corporate Officer, PHC Group 9
Slide 10: A Long History of Innovation and Market Share Gains
A Long History of Innovation and Market Share Gains • Contour® Next is the #1 selling BGM strip globally • #1 or #2 position in 18 out of 26 measured countries • Gained share in 19 out of 26 measured countries Source: IQVIA, IRI, Symphony Metys®, and other 3rd party syndicated data; MAT November 202
Slide 11: Eversense: 3 Generations of a Highly Differentiated Solution
Eversense: 3 Generations of a Highly Differentiated Solution First launched in 2016, Eversense® is now on E3, its 3rd generation product with both FDA and CE approvals 2016-2017 2018 2022 Eversense® System (90-day) Eversense® System (90-day) NEW Eversense® E3 System (180-day) Eversense® XL System (1
Slide 12: CGM Market Continues to Expand
CGM Market Continues to Expand $14 Billion Market Opportunity 12
Slide 13: Vast majority of people with diabetes are interested in E3
Vast majority of people with diabetes are interested in E3 75% of users who Would Consider Eversense E3 have heard of NOT HEARD OF EVERSENSE® 39% 18% 43% Eversense® would HEARD OF EVERSENSE® 9% 15% 75% consider E3 as their CGM solution No Maybe Yes Source: Ascensia primary market research, December
Slide 14: Eversense addresses unmet needs
Eversense addresses unmet needs as... the FIRST and ONLY long-term CGM system... ▪ Lasts for 6 months vs days ▪ System with fresh, gentle-on skin adhesive patch ▪ Transmitter that is removable ▪ Achieves 8.5% MARD* ▪ System with on-body vibe alerts for hypo and hyper warnings ▪ Device that does not
Slide 15: Commercial Strategy – Sales and Marketing
Commercial Strategy – Sales and Marketing Geographic Focus US: 60 dedicated sales people generating HCP leads OUS: Leverage sizable BGM infrastructure Approximately 1200 augmented by a dedicated patients in the U.S. Eversense team Direct to Consumer Marketing • 50,000 leads generated in the past 1 y
Slide 16: Commercial Strategy – Payer Coverage
Commercial Strategy – Payer Coverage US: • Strong payer coverage including Medicare and almost all major national insurers • ~250M covered lives 16
Slide 17: Commercial Strategy – Prescribers and Inserters
Commercial Strategy – Prescribers and Inserters US: 230 active certified inserters and 680 prescribers OUS: 600+ inserters 17
Slide 18: The Nurse Practitioner Group Improves Access to Procedures
The Nurse Practitioner Group Improves Access to Procedures • Network of 10,000+ healthcare professionals • NPs, MDs, PAs, Clinical Psychologists, RNs, MAs, etc. • 35 states and 50 cities • Women led – Minority Owned – Highly Energetic and Motivated • Flexible / Remote task force • 5 Office Locations
Slide 19: Eversense Users and Growth Targets – 5% in 5 Years
Eversense Users and Growth Targets – 5% in 5 Years Global Eversense Revenue >$500M Future Device Features to Enable → 5% global CGM market share Market Share Goal: → Expand patient base • Pump and Smart Pen integration • Flash monitoring option <1% global CGM market share → Improve ease of use • Red
Slide 20: Eversense® is critical to Ascensia’s Mission
Eversense® is critical to Ascensia’s Mission 20
Slide 21: Thank You
pric fe THANK YOU. | Senseonics.
Slide 22: Eversense CGM System addresses unmet needs
Eversense E3 System Eversense CGM System addresses unmet needs First and only CGM that lasts for 6 months Fully implantable 3rd generation sensor Sensor Smart Transmitter PROMISE study demonstrated proven top tier safety and accuracy achieving 8.5% MARD Mobile App System with on-body vibe alerts for
Slide 23: Portfolio Overview
Portfolio Overview 2022 2023 2024 2025 180-day Sensor iCGM Approval Approval iCGM data will be 365-day Sensor Pivotal Trial Initiated available for analysis Submit to FDA Complete Gemini Gemini feasibility study Submit IDE indication Incorporate battery power Complete Freedom feasibility Initiate Fr
Slide 24: ENHANCE Pivotal Study for Eversense 365-day System
ENHANCE Pivotal Study for Eversense 365-day System 1 sensor per year Fully enrolled in the ENHANCE pivotal clinical study Received FDA IDE approval to include pediatric cohort On track to submit data in six months for iCGM claim 24 Product development timelines and specifications subject to risks an
Slide 25: Gemini System
GEMINI SYSTEM Autonomous sensor testing with data processing capabilities enabling 2 products from 1 platform CGM with Transmitter • Enhanced ROME2 sensor with integrated battery • Full year use with 1 sensor and 1 cal/week • For all insulin and non-insulin using Standalone Therapeutic patients FGM
Slide 26: Freedom System
FREEDOM SYSTEM Elimination of Transmitter by incorporating BLE in the sensor Enhanced ROME2 sensor with integrated battery and BLE communication Full year use with 1 sensor and 1 cal/week No transmitter included in the System Direct communication between sensor and handheld 26 Product development ti
Slide 27: 2022 Financial Performance
2022 Financial Performance 27
Slide 28: Commercial Relationship Impact to Senseonics Revenue
Commercial Relationship Impact to Senseonics Revenue Senseonics Ascensia Distributors HCP / Patient 1 Day 0 Day 90 Day 180 Eversense vs. Senseonics Revenue CAGR 2 50% delta Eversense Senseonics 28 2022 2023 2024 2025 Projected share of revenue based on existing Collaboration Agreement provisions and
Slide 29: Key Financial Targets (Preliminary Projections)
Key Financial Targets* (Preliminary Projections) SENS 2023 2024 2025 SENS Revenue Share % 70.0% - 75.0% 60.0% - 65.0% 60.0% - 65.0% Senseonics Revenue $ 20.0 - $ 24.0 $ 40.0 - $ 50.0 $ 100.0 - $ 120.0 Gross Margin 7.5% - 12.5% 25.0% - 30.0% 35.0% - 40.0% Operating Expenses $ 75.0 - $ 85.0 $ 75.0 - $
Slide 30: Appendix A – Key Assumptions for Financial Targets
Appendix A – Key Assumptions for Financial Targets Overall Product Approval • Ranges of Financial Targets are based on the current • Assumed FDA approval of the 365- Ascensia forecast presented day product in the US mid 2024 and • Revenue for Senseonics is assumed to be recognized in launched in Q4
Slide 31: Q&A
Q&A Tim Goodnow, CEO & Rick Sullivan, CFO Koichiro Sato, COO Robert Schumm, President 31